119 related articles for article (PubMed ID: 36994761)
1. Practical delta check limits for tumour markers in different clinical settings.
Yu S; Shin KH; Shin S; Lee H; Yoo SJ; Jun KR; Shin H; Kim S
Clin Chem Lab Med; 2023 Sep; 61(10):1829-1840. PubMed ID: 36994761
[TBL] [Abstract][Full Text] [Related]
2. Machine learning-based delta check method for detecting misidentification errors in tumor marker tests.
Seok HS; Choi Y; Yu S; Shin KH; Kim S; Shin H
Clin Chem Lab Med; 2023 Dec; ():. PubMed ID: 38095534
[TBL] [Abstract][Full Text] [Related]
3. Tumour Marker Requisition Pattern in a Tertiary Care Centre of Eastern Nepal.
Niraula A; Gelal B; Chaudhari RK; Das BK; Lamsal M
Kathmandu Univ Med J (KUMJ); 2022; 20(80):422-426. PubMed ID: 37795716
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Application Biological Variation and Patient Data for Selecting Delta Check Limits.
Huang Y; Song L; Li Y; Dai W; Zhang PA
Clin Lab; 2020 Sep; 66(9):. PubMed ID: 32902210
[TBL] [Abstract][Full Text] [Related]
5. Application and optimization of reference change values for Delta Checks in clinical laboratory.
Hong J; Cho EJ; Kim HK; Lee W; Chun S; Min WK
J Clin Lab Anal; 2020 Dec; 34(12):e23550. PubMed ID: 32862477
[TBL] [Abstract][Full Text] [Related]
6. Multicentre tumour marker reference range study.
Wilson AP; Van Dalen A; Sibley PE; Kasper LA; Durham AP; el Shami AS
Anticancer Res; 1999; 19(4A):2749-52. PubMed ID: 10470234
[TBL] [Abstract][Full Text] [Related]
7. Tumour markers with clinically controlled cut-offs for suspected cancer.
Bosch X; Molina R; Marrades R; Augé JM; Pellicé M; López-Soto A
Eur J Clin Invest; 2021 Jul; 51(7):e13523. PubMed ID: 33594702
[TBL] [Abstract][Full Text] [Related]
8. Effective and Practical Complete Blood Count Delta Check Method and Criteria for the Quality Control of Automated Hematology Analyzers.
Kim MS; Park CJ; Namgoong S; Kim SI; Cho YU; Jang S
Ann Lab Med; 2023 Sep; 43(5):418-424. PubMed ID: 37080742
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. The clinical significance in healthy men of the association between obesity related plasma hemodilution and tumor marker concentration.
Chang IH; Ahn SH; Han JH; Kim TH; Kim YS; Myung SC
J Urol; 2009 Feb; 181(2):567-72; discussion 572-3. PubMed ID: 19084848
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of tumour marker velocity of cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in breast cancer surveillance.
Hing JX; Mok CW; Tan PT; Sudhakar SS; Seah CM; Lee WP; Tan SM
Breast; 2020 Aug; 52():95-101. PubMed ID: 32485607
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of abnormal levels of serum tumour markers in elderly people.
Lopez LA; Del Villar V; Ulla M; Fernandez F; Fernandez LA; Santos I; Rabadan L; Gutierrez M
Age Ageing; 1996 Jan; 25(1):45-50. PubMed ID: 8670528
[TBL] [Abstract][Full Text] [Related]
13. Tumour markers in rheumatoid arthritis-associated interstitial lung disease.
Wang T; Zheng XJ; Ji YL; Liang ZA; Liang BM
Clin Exp Rheumatol; 2016; 34(4):587-91. PubMed ID: 27213221
[TBL] [Abstract][Full Text] [Related]
14. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
15. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.
Vergis R; Corbishley CM; Norman AR; Bartlett J; Jhavar S; Borre M; Heeboll S; Horwich A; Huddart R; Khoo V; Eeles R; Cooper C; Sydes M; Dearnaley D; Parker C
Lancet Oncol; 2008 Apr; 9(4):342-51. PubMed ID: 18343725
[TBL] [Abstract][Full Text] [Related]
16. Reference limits for chromogranin A, CYFRA 21-1, CA 125, CA 19-9 and carcinoembryonic antigen in patients with chronic kidney disease.
Mikkelsen G; Åsberg A; Hultström ME; Aasarød K; Hov GG
Int J Biol Markers; 2017 Oct; 32(4):e461-e466. PubMed ID: 28561881
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of tumour markers in pleural effusions.
Volarić D; Flego V; Žauhar G; Bulat-Kardum L
Biochem Med (Zagreb); 2018 Feb; 28(1):010706. PubMed ID: 29472801
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of biological variation in the establishment of delta check limits.
Lee J; Kim SY; Kwon HJ; Lee HK; Kim Y; Kim Y
Clin Chim Acta; 2016 Dec; 463():18-21. PubMed ID: 27524506
[TBL] [Abstract][Full Text] [Related]
19. Reference intervals for carcinoembryonic antigen (CEA), CA125, MUC1, Alfa-foeto-protein (AFP), neuron-specific enolase (NSE) and CA19.9 from the NORIP study.
Bjerner J; Høgetveit A; Wold Akselberg K; Vangsnes K; Paus E; Bjøro T; Børmer OP; Nustad K
Scand J Clin Lab Invest; 2008; 68(8):703-13. PubMed ID: 18609108
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
Giesing M; Suchy B; Driesel G; Molitor D
BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
